[go: up one dir, main page]

HK1105634B - Heteroatoms-containing tricyclic compounds - Google Patents

Heteroatoms-containing tricyclic compounds Download PDF

Info

Publication number
HK1105634B
HK1105634B HK07110850.1A HK07110850A HK1105634B HK 1105634 B HK1105634 B HK 1105634B HK 07110850 A HK07110850 A HK 07110850A HK 1105634 B HK1105634 B HK 1105634B
Authority
HK
Hong Kong
Prior art keywords
organic solvent
epi
chloro
chlorinating agent
base
Prior art date
Application number
HK07110850.1A
Other languages
German (de)
French (fr)
Chinese (zh)
Other versions
HK1105634A1 (en
Inventor
Maximilian Grassberger
Amarylla Horvath
Original Assignee
Meda Pharma S.À.R.L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0422643A external-priority patent/GB0422643D0/en
Priority claimed from GB0427599A external-priority patent/GB0427599D0/en
Application filed by Meda Pharma S.À.R.L. filed Critical Meda Pharma S.À.R.L.
Priority claimed from PCT/EP2005/010889 external-priority patent/WO2006040111A2/en
Publication of HK1105634A1 publication Critical patent/HK1105634A1/en
Publication of HK1105634B publication Critical patent/HK1105634B/en

Links

Description

The present invention relates to heteroatoms-containing tricyclic compounds, e.g. a process for the production of 33-epichloro-33-desoxyascomycin (33-epi-33-chloro-FR 520).
33-Epi-33-chloro-FR 520 is a known compound, e.g. disclosed in EP0427680 (example 66a). 33-Epi-33-chloro-FR 520 of formula may be useful in immunological-mediated diseases, e.g. useful in the treatment and prevention of inflammatory, auto-immune and hyperproliferative diseases, e.g. including
  • skin diseases, such as psoriasis, atopic dermatitis,
  • immune-mediated conditions of the eye, such as auto-immune diseases, e.g. including uveitis, keratoplasty and chronic keratitis,
  • allergic conditions, e.g. vernal conjunctivitis, inflammatory conditions, corneal transplants.
Processes for the production of 33-Epi-33-chloro-FR 520 are known. We have now found surprisingly a process for the production of 33-Epi-33-chloro-FR 520 from FR520 (ascomycin) in which process the use of protecting groups may be avoided. Such process may be carried out in one single chemical process step.
In one aspect the present invention provides an one-step process for the production of 33-Epi-33-chloro-FR 520 from FR520.
In another aspect the present invention provides a process for the production of 33-epi-33-chloro-FR 520 from FR520 wherein protecting groups are avoided, e.g. wherein protecting group technology is avoided.
In another aspect the present invention provides a process for the production of 33-Epi-33-chloro-FR 520 comprising reacting the compound FR520 with an appropriate chlorinating agent in organic solvent, optionally in the presence of a base, and isolating 33-Epi-33-chloro-FR 520 obtained from the reaction mixture.
In a process according to the present invention FR520, the chlorinating agent and optionally the base, optionally each in organic solvent, or as such, are mixed and the mixture obtained is stirred at appropriate temperature for a period sufficient for reaction. The reaction mixture obtained may be worked up, e.g. analogously to a method as conventional, e.g. by aqueous extraction and evaporation of the organic solvent. The work up residue obtained comprising 33-Epi-33-chloro-FR 520 may be further purified, e.g. by chromatography, crystallization.
An appropriate chlorinating agent includes e.g. dichlorotriphenylphosphorane. The chlorinating agent may be used as such or may be provided in situ, e.g. by treating triphenylphosphine with a chlorinated alkane, e.g. (C1-2)alkane, such as CCl4, C2Cl6, preferably CCl4; or by addition of triphenylphosphine to N-chlorosuccinimide in organic solvent.
Organic solvent includes appropriate organic solvent, such as hydrocarbons, e.g. aromatic hydrocarbons, e.g. benzene, toluene; ethers, such as tetrahydrofurane; nitriles, e.g. acetonitrile; chlorinated alkanes, such as CCl4 and mixtures of individual cited solvent. E.g., the reaction mixture may be diluted with a second solvent, e.g., if as the organic solvent toluene is used, preferably with acetonitrile, in order to facilitate stirring. Preferably organic solvent includes toluene, acetonitrile or tetrahydrofurane, or optionally a mixture of toluene and acetonitrile, in case of using triphenylphosphine and N-chlorosuccinimide for the preparation of dichlorotriphenylphosphorane as a chlorinating agent. Preferably organic solvent includes a halogenated alkane in case of using triphenylphosphine and a halogenated alkane for the preparation of dichlorotriphenylphosphorane as a chlorinating agent.
In another aspect the organic solvent in a process of the present invention is selected from the group consisting of aromatic hydrocarbons, ethers and nitriles.
In case of using triphenylphosphine and a chlorinated alkane as a solvent, the chlorinated alkane may be used in one aspect as a halogen source for the production of dichlorotriphenylphosphorane and, in another aspect, as organic solvent, although the addition of further organic solvent, e.g. such as cited above, is not excluded.
Appropriate reaction temperatures include temperatures from room temperature to about 100°C, such as from room temperature to about 80°C, e.g. from room temperature to about 70°C, e.g. from room temperature to 70°C, 80°C or 100°C. In case of using a chlorinated alkane and triphenylphosphine for the production of the chlorinating agent, such as CCl4, preferably the reaction temperature is reflux temperature of the chlorinated alkane.
E.g. FR520 is treated with dichlorotriphenylphosphorane, e.g. dichlorotriphenylphosphorane is provided by treating triphenylphosphine with
  • N-chlorosuccinimide in organic solvent, e.g. organic solvent as described above, preferably an ether or an aromatic hydrocarbon,
  • chlorinated alkanes as a chlorinating agent and as a solvent, such as CCl4, in which case no further organic solvent is necessary, although the addition of further organic solvent, e.g. such as described above, is not excluded,
  • solid chlorinated alkanes in organic solvent, such as C2Cl6 in organic solvent, e.g. organic solvent as described above, preferably an ether or an aromatic hydrocarbon,
optionally in the presence of a base.
A base includes appropriate bases, such as organic bases, e.g. nitrogen containing bases, preferably such as tert.amines or heterocyclic bases containing at least one nitrogen atom, more preferably aromatic heterocyclic bases, such as a pyridine, an imidazole; preferably a pyridine, such as pyridine, 2,4,6-trimethylpyridine (s-collidine).
In the case of using triphenylphosphine and a chlorinated alkane for the production of a chlorinating agent, during the reaction of FR520 with the chlorinating agent a base optionally may be present. In case of using triphenylphosphine and N-chlorosuccinimide for the production of a chlorinating agent during the reaction of FR520 with the chlorinating agent the presence of a base is preferred, e.g. a base should be present.
In a preferred aspect of the present invention N-chlorosuccinimide is treated with triphenylphosphine in organic solvent and, to the mixture obtained, a base and FR520 are added, e.g. in portions, under stirring and heating.
In another aspect the present invention provides a process for the production of 33-Epi-33-chloro-FR 520, comprising reacting FR 520 in organic solvent with a chlorinating agent in the presence of a base, e.g. under appropriate temperature, wherein the chlorinating agent is provided by treating triphenylphosphine with N-chlorosuccinimide in organic solvent.
In another preferred aspect of the present invention triphenylphosphine is treated with a chlorinated alkane and FR 520 is added under stirring and heating.
In another aspect the present invention provides a process for the production of 33-Epi-33-chloro-FR 520 from FR520, comprising reacting FR 520 with a chlorinating agent in organic solvent, e.g. under appropriate temperature, wherein the chlorinating agent is provided by treating triphenylphosphine with a chlorinated alkane, e.g. wherein the organic solvent preferably is a chlorinated alkane, e.g. in the absence of a base.
The ratio of FR520 and the chlorinating agent should be at least an equivalent ratio, preferably an excess of the chlorinating agent is used, e.g. ascomycin and the chlorinating agent a used in a ratio from about 1:1 to about 1:3 (per equivalent of ascomycin 1 to 3 equivalents of the chlorinating agent), such as from about 1:1 to about 1:2, e.g. from about 1:1 to about 1:5, preferably from about 1:1 to about 1:1.3, e.g. a ratio from 1:1 to 1:3, such as from 1:1 to 1:2, e.g. from 1:1 to 1:5, preferably from 1:1 to 1:1.3 may be appropriate. The ratio of FR520 and the base should be at least an equivalent ratio, preferably an excess of the base is used, e.g. FR520 and the base are used in a ratio from about 1:1 to about 1:10 (per equivalent FR520 1 to 10 equivalents of the base), such as from about 1:2 to about 1:10, e.g. from about 1:3 to about 1:9, preferably from about 1:4 to 1:8; , e.g. a ratio from 1:1 to 1:10, such as from 1:2 to 1:10, e.g. from 1:3 to 1:9, preferably from 1:4 to 1:8 may be appropriate.
After a sufficient period of time which period may be determined by e.g. thin layer chromatography or HPLC, the mixutre obtained comprising FR520, the chlorinating agent and optionally a base, is worked up. Work up may be preferably carried out by subjecting to aqueous extraction. From the organic phase obtained by extraction, solvent may be removed, e.g. by distillation, such as evaporation, and the (distillation, evaporation) residue obtained may be subjected to further purification, e.g. subjected to chromatography, e.g. subjected to chromatography over silicagel. 33-Epi-33-chloro-FR 520 is obtained and may be crystallized as appropriate, e.g. from a mixture of water and ethanol.
From chromatography optionally unreacted ascomycin may be recollected. Recollected ascomycin may again undergo a reaction according to the present invention.
FR520 is a compound of formula
In the following examples all temperatures are in degree centigrade and are uncorrected. The following abbreviations are used:
FR520
ascomycin, compound of formula ASC
33-epi-33-chloro-FR 520
33-epichloro-33-desoxyascomycin (pimecrolimus), compound of formula I
Example 1 33-Epi-33-chloro-FR 520
9.69 g of s-collidine (2,4,6-trimethylpyridine) and 15.84 g of FR520 are added to a solution of 24.8 mMol of dichlorotriphenylphosphine in 160 ml of toluene. The mixture obtained is stirred at 60° for 1 hour, H2O is added, two phases obtained are separated and the organic layer obtained is washed with aqueous, saturated NaCl solution and dried. From the mixture obtained solvent is evaporated and the evaporation residue obtained is subjected to chromatography over silicagel. 33-epi-33-chloro-FR 520 is obtained. Yield: 51.4%.
From chromatography a fraction containing unreacted FR520 is obtained. The fraction containing unreacted FR520 is triturated with diethylether and 4.5 g of crude ascomycin are obtained which may undergo a reaction as described in example 1 above or in any of the examples 2 or 3 below.
Analogously as described in example 1 but using FR520, dichlorotriphenylphosphine and organic solvent and bases as set out in TABLE 1 below, in amounts and ratios as set out in TABLE 1 below, 33-epi-33-chloro-FR 520 is obtained in yields (%) as set out in TABLE 1 below. TABLE 1
1a 0.2 1:1.25:4 pyridine toluene 55.4
1b 2.0 1:1:4 pyridine toluene 58.6
1c 2.0 1:1:8 pyridine toluene 40.7
1d 2.0 1:1.25:5.5 imidazole acetonitrile 13.6
1e 2.0 1:1.25:5.5 pyridine acetonitrile 32.4
1f 2.0 1:1.2:4 s-collidine toluene 60.0
1g 10 1:1.2:4 pyridine toluene 52.4
1h 48 1:1.1:4 pyridine toluene 48.8
1i 1:1.2:4 s-collidine toluene 33.8
TABLE 1
In TABLE 1 above FR520 (g) means the amount of FR520 in gram, "RATIO FR520:CL-A:BASE" means the molar ratio of FR520 : dichlorotriphenylphosphine : base; and "EX" means the Example number.
Example 2 33-Epi-33-chloro-FR 520
A solution of 277 mg of FR520 and 138 ml of triphenylphosphine in 8 ml of CCl4 is heated to reflux for 18 hours. To the mixture obtained toluene is added, the mixture obtained is filtrated and from the filtrate obtained solvent is evaporated. The evaporation residue is subjected to chromatography over silicagel. 33-Epi-33-chloro-FR 520 is obtained. Yield: 45%.
Example 3 33-Epi-33-chloro-FR 520
A solution of 100 mg triphenylphosphine in 1 ml of tetrahydrofurane (THF) is added dropwise to 50 mg of N-chlorosuccinimide in 1.2 ml of THF. The mixture obtained is stirred for 0.5 hours at room temperature and 0.1 ml pyridine followed by a solution of 244 mg of FR520 in 2 ml of THF are added and the mixture obtained is stirred for 1 hour at 65°. The mixture is diluted with toluene, water is added, and the two phases obtained are separated. The organic layer obtained is washed with 1 N HCl, H2O and saturated NaCl solution and dried. From the solution obtained solvent is evaporated and the evaporation residue obtained is subjected to chromatography over silicagel. 33-Epi-33-chloro-FR 520 is obtained. Yield: 48.1%.
Example 4 Crystallization of 33-Epi-33-chloro-FR 520
27 g of crude 33-epi-33-chloro-FR 520, obtained according to a method as described in any of the examples 1 to 3, are dissolved in 180 ml of ethanol and 65 ml water are added. The mixture obtained is kept at 4°, further water is added and the mixture obtained is kept for further 4 hours at 4°. 23.5 g of crystallized 33-epi-33-chloro-FR 520 are obtained in a purity of 98%.

Claims (7)

  1. A one-step process for the production of a compound of formula from a compound of formula wherein protecting groups are avoided, comprising reacting the compound of formula ASC with an appropriate chlorinating agent in organic solvent, optionally in the presence of a base, and isolating a compound of formula I obtained from the reaction mixture.
  2. A process according to claim 1, wherein the chlorinating agent is dichlorotriphenylphosphorane.
  3. A process according to claim 1 or claim 2, comprising reacting the compound of formula ASC as defined in claim 1, in organic solvent with dichlorotriphenylphosphorane in the presence of a base, wherein the dichlorotriphenylphosphorane is provided by treating triphenylphosphine with N-chlorosuccinimide in organic solvent.
  4. A process according to claim 3, wherein the organic solvent is selected from the group consisting of aromatic hydrocarbons, ethers and nitriles.
  5. A process according to any one of claims 1 to 4, wherein the base is pyridine.
  6. A process according to claim 1 or 2, comprising reacting a compound of formula ASC with dichlorotriphenylphosphorane in organic solvent, wherein dichlorotriphenylphosphorane is provided by treating triphenylphosphine with a chlorinated alkane.
  7. A process according to claim 6, wherein the chlorinated alkane is CCl4.
HK07110850.1A 2004-10-12 2005-10-10 Heteroatoms-containing tricyclic compounds HK1105634B (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0422643.7 2004-10-12
GB0422643A GB0422643D0 (en) 2004-10-12 2004-10-12 Organic compounds
GB0427599A GB0427599D0 (en) 2004-12-16 2004-12-16 Organic compounds
GB0427599.6 2004-12-16
PCT/EP2005/010889 WO2006040111A2 (en) 2004-10-12 2005-10-10 Heteroatoms-containing tricyclic compounds

Publications (2)

Publication Number Publication Date
HK1105634A1 HK1105634A1 (en) 2008-02-22
HK1105634B true HK1105634B (en) 2012-10-26

Family

ID=

Similar Documents

Publication Publication Date Title
US4427587A (en) Total synthesis of antitumor antibiotics BBM-2040A and BBM-2040B
WO2010126820A2 (en) Preparation of alkyl esters of n-protected oxo-azacycloalkylcarboxylic acids
SE457084B (en) N-METHYL-11-AZA-10-DEOXO-10-DIHYDROERYTROMYCINE AND DERIVATIVES AND PROCEDURES FOR PREPARING THEREOF
IL182307A (en) Heteroatoms-containing tricyclic compounds
González-Gómez et al. Novel chemistry of β-carbolines. Expedient synthesis of polycyclic scaffolds
RU2118323C1 (en) Method for production of derivative of ergoline
Yasuda et al. Preparation of crystallinep-nitrobenzyl 2-hydroxymethyl carbapenem as a key intermediate for the anti-MRS carbapenem L-786,392
EP2080761A1 (en) Compounds
HK1105634B (en) Heteroatoms-containing tricyclic compounds
CN111233750A (en) 3, 3-difluoro-1, 2,3, 6-tetrahydropyridine derivatives and preparation method thereof
US20100249394A1 (en) Processes for producing decitabine
US5508397A (en) Activated macrolactams
JPH0246577B2 (en)
Paul et al. Synthesis of new series of iboga analogues
Nair Novel unsaturated purine nucleosides
US4006160A (en) Process for the synthesis of N-hydroxypyrroles, N-hydroxyimidazoles, and derivatives thereof
Hutchinson et al. Adenosine receptor ligands with oxygenated N6-substituents
DE69520554T2 (en) METHOD FOR PRODUCING INDOLOCARBAZOL DERIVATIVES
EP0564006A2 (en) Process for preparing purine derivatives and novel purine derivatives
Paparin et al. Synthesis of 2, 5‐bis‐arylpyridines by [4+ 2] cycloaddition of 1, 4‐bis aryl‐2‐aza‐1, 3‐butadienes with electron‐poor dienophiles
CZ120799A3 (en) Process for preparing pharmaceutical intermediates
Nitta et al. On the reaction of tricarbonyl (4–7-η-1 H-1, 2-diazepine) iron with activated acetylenes. Preparation of 1-vinyl-1 H-1, 2-diazepine derivatives
EP0614909B1 (en) Method for selective acylation of estradiol
Uoyama et al. Preparation of biphenylene-and benzocyclooctene-fused heterocycles
JPH05247056A (en) Indolocarbazole derivative